The study included 132 patients treated between 2021 and 2024, all of whom had at least two brain metastases and underwent microsurgical resection of one or more selected lesions. In this population, surgery is rarely curative in the conventional sense. Surgeons operate either to relieve symptoms caused by a mass pressing on critical brain structures, or to obtain tissue for histopathologic diagnosis when the primary cancer or its molecular profile remains uncertain. Because most of the tumor burden remains elsewhere in the brain, the operation is a calculated intervention whose value depends entirely on whether the patient lives long enough, and recovers well enough, to benefit from it.

The headline finding is stark: the ninety-day mortality rate was 28 percent, with 37 of the 132 patients dying within three months of surgery. That figure alone reframes the conversation around surgery for multiple metastases, a field where much of the historical literature has focused on carefully selected single-lesion patients. The median age of the cohort was 63 years, roughly 41 percent were women, and about two-thirds of patients had between two and four metastases while nearly a third had five or more. The median resected tumor volume was 15.4 cubic centimeters, quantified through volumetric assessment of magnetic resonance imaging rather than the crude diameter measurements used in many older studies.

What elevates the work beyond a simple outcome audit is its systematic search for preoperative predictors. Four factors emerged as significantly associated with increased ninety-day mortality: advanced age, a lower preoperative Karnofsky Performance Status, the absence of adjuvant treatment after surgery, and a higher score on the five-item modified frailty index. Each of these captures a different dimension of physiological reserve. Age reflects cumulative biological wear; the Karnofsky score, a scale from 0 to 100 that grades a patient’s functional independence, measures how much the disease has already eroded daily functioning; the frailty index aggregates comorbidities such as diabetes, cardiac disease and functional dependence into a compact vulnerability score; and adjuvant therapy, whether radiotherapy or systemic treatment, addresses the residual disease that surgery cannot touch.

The statistical relationships were strong. Age and lack of adjuvant treatment each reached p-values below 0.001, meaning the probability that these associations arose by chance is vanishingly small. The frailty index was associated with mortality at p = 0.008, and Karnofsky status at p = 0.048. Notably, the sheer number of metastases and the volume of the resected tumor did not predict early death. This is a counterintuitive and clinically important result: it suggests that the decision to operate should hinge less on how many lesions a patient carries, and more on who the patient is physiologically when they arrive in the operating room.

Survival was not the only endpoint. The researchers also examined where patients went after discharge, how long they stayed in the hospital, and whether they were allocated to adjuvant treatment. Here, two variables dominated. Patients with lower preoperative Karnofsky scores and higher frailty index scores were significantly more likely to be discharged to institutional care rather than to their own homes, with both associations reaching p-values below 0.001. For patients and families weighing surgery against symptom-directed care, this is a concrete and often underappreciated consideration: the operation may relieve pressure and clarify diagnosis, but in frail or functionally compromised patients it may also mark the transition from independent living to a nursing facility.

Length of postoperative hospital stay told a similar story through correlation analysis. Stay duration correlated inversely with Karnofsky status, with a Spearman rank correlation coefficient of rs = -0.29 and p = 0.001, meaning weaker patients stayed longer. It correlated positively with the frailty index at rs = 0.26 and p = 0.003. Once again, age, tumor volume and the number of lesions showed no significant relationship with recovery time. The pattern is consistent and mechanistically plausible: functional reserve and frailty govern how quickly a brain recovers from surgery, how well wounds heal, and how quickly complications such as confusion, weakness or infection can be overcome, whereas the anatomical extent of metastatic disease matters less for the perioperative trajectory.

The findings arrive at a moment when the treatment landscape for brain metastases is shifting rapidly. Stereotactic radiosurgery, which delivers precisely focused radiation to multiple lesions in a single session without opening the skull, has become the default for many patients with limited metastatic burden, supported by large prospective studies such as the JLGK0901 trial. Meanwhile, targeted therapies and immunotherapies increasingly penetrate the blood-brain barrier, allowing systemic treatment to control intracranial disease in ways that were unimaginable two decades ago. Surgery has retained a defined but narrower role: large symptomatic lesions threatening herniation or severe neurological deficit, and diagnostic uncertainty that blocks access to molecularly matched treatment. Within that narrowed role, knowing who benefits and who is harmed becomes paramount, which is precisely the gap this study addresses.

The authors are careful about the implications. They do not argue that frail, elderly or functionally impaired patients should be denied surgery outright; rather, they state that resection for symptom relief or tissue diagnosis in patients with multiple metastases may be performed with these precautions in mind. In practice, that means the four risk factors should be part of the preoperative conversation. A 78-year-old with a Karnofsky score of 50, a frailty index of three out of five, and no realistic prospect of adjuvant therapy carries a fundamentally different risk profile from a 58-year-old who is functionally independent, robust, and eligible for radiosurgery or targeted drugs afterward. Quantifying that difference before consent is obtained is the essence of risk stratification, and it converts a vague warning about being a poor candidate into a structured, evidence-based assessment.

There are limits worth keeping in view. The study is retrospective and bicentric, drawing on two academic centers in Germany and Austria, so selection biases in who was offered surgery cannot be fully excluded, and the ninety-day window captures early perioperative harm but not longer-term survival or quality of life. The frailty index, while practical, is a coarse instrument compared with comprehensive geriatric assessment. Still, the message for oncology teams is actionable and timely: in the era of powerful non-surgical options for multiple brain metastases, the bar for operative intervention is set not by the tumor map alone, but by age, frailty, functional status and the availability of subsequent therapy. Patients with multiple brain metastases and their families should expect those four factors to be weighed explicitly, and documented, before anyone is wheeled into the operating theater.

Subject of Research: Risk stratification for surgical outcomes in patients with multiple brain metastases

Article Title: Risk stratification for unfavorable outcome after resection of selected brain metastases in patients with multiple brain metastases

Article References: Eibl, T., Mercea, P. A., Liebert, A., Ritter, L., Rossmann, J., Rezai, A., Moskwa, M., Hurtig, H., Stadler, C., Wunderlich, S., Feldheim, J., Liman, J., Schwartz, C., Griessenauer, C. J., & Schebesch, K.-M. (2026). Risk stratification for unfavorable outcome after resection of selected brain metastases in patients with multiple brain metastases. Journal of Neuro-Oncology, 180(1), Article 9. https://doi.org/10.1007/s11060-026-05819-6

Image Credits: AI Generated

DOI: 10.1007/s11060-026-05819-6

Keywords: brain metastases, neurosurgery, risk stratification, Karnofsky Performance Status, frailty index, 90-day mortality, tumor resection, adjuvant therapy, stereotactic radiosurgery, Journal of Neuro-Oncology, prognostic factors, cancer surgery

The new study, published in the Proceedings of the National Academy of Sciences, was led by Mahdiyeh Shahi, a former graduate student at Purdue who is now a clinical chemistry postdoctoral fellow at the University of Minnesota Medical School, together with R. Graham Cooks, the Henry Bohn Hass Distinguished Professor of Chemistry in Purdue’s James Tarpo Jr. and Margaret Tarpo Department of Chemistry. The pair collaborated with Dr. Alfredo Quiñones-Hinojosa, a professor of neurosurgery at the Mayo Clinic in Jacksonville, Florida, along with his postdoctoral fellow Loizos Michaelides and other Mayo colleagues, to develop and test a mass spectrometry method designed specifically for the constraints of the operating room. The work draws on an analytical tradition that Cooks himself helped launch more than two decades ago.

Mass spectrometry, at its core, is a way of weighing molecules. The technique ionizes chemical compounds and measures their mass-to-charge ratios, allowing researchers to identify and quantify the complex mixture of metabolites, lipids, and other molecules present in a sample. In a clinical context, that molecular fingerprint can reveal things that conventional microscopy cannot: whether tissue is cancerous, which subtype of tumor it belongs to, and even which genetic mutations the tumor carries. The obstacle has always been speed and practicality. Traditional mass spectrometry requires extensive sample preparation, vacuum systems, and lengthy analysis, none of which fits a surgical workflow in which decisions must be made in minutes.

The Purdue method sidesteps those constraints through ambient ionization, an approach invented at Purdue and first described in 2004. Instead of preparing samples inside sealed vacuum chambers, ambient ionization creates ions from molecules in the open environment, permitting molecular measurements to be made essentially in place. The technique has since been commercialized and widely adopted. The specific variant used in the new study, called syringe touch spray, is strikingly simple: an ordinary hypodermic needle takes a sample from the patient, and the needle itself becomes the ionization source for the mass spectrometric analysis. No elaborate extraction, no separate sampling step, no fundamental redesign of surgical practice.

In the study, the researchers analyzed 86 human brain samples obtained through MRI-guided precision surgery at the Mayo Clinic. During such operations, a small number of samples are taken from surgeon-defined positions in the brain for pathological examination. The team transferred fractions of those samples onto the plunger of a hypodermic needle and sprayed a solution that enabled measurement of the ratio of signals for multiple pairs of endogenous compounds in the brain, using tandem mass spectrometry. The entire measurement took roughly three minutes. Rather than hunting for a single biomarker, the method relies on ratiomics: comparing the relative abundance of pairs of metabolites that naturally occur in brain tissue, which proved far more robust than absolute concentrations that can vary with sample handling.

The results were unambiguous. Ratios of endogenous metabolites distinguished glioma from non-tumor tissue with high confidence, and the same measurements classified tumor subtypes and mutation status, information that normally requires days of laboratory work after surgery. Cooks emphasized that the simple ambient ionization approach enables fast, clinically compatible analysis with the potential to improve margin assessment and enhance patient outcomes. Because glioma cells spread into nearby healthy brain tissue, particularly at the tumor margins, they are notoriously difficult to detect with the conventional technologies available in the operating room. Tissue left behind after surgery can seed recurrence and make subsequent treatment more difficult, so every improvement in margin detection carries direct consequences for survival.

Shahi stressed that the molecular information produced by the technique is simply not available under current standard-of-care procedures. If the diagnostic method were approved for clinical use, she explained, it would provide actionable molecular information during surgery, on a time scale compatible with the operation itself, whereas current pathology results arrive only after hours. That information could directly influence treatment, including the extent of tumor resection, although the final surgical decision would rest with the surgeon weighing the overall clinical context rather than the mass spectrometry results alone. She also noted that the molecular profiles could help guide the selection of targeted therapies, extending the technique’s value beyond the operating room into treatment planning.

Importantly, the researchers are careful to position the technology as an addition to, not a replacement for, existing practice. Cooks noted that the technology would not displace the current standard of care during brain tumor surgery. Instead, it could provide surgeons with molecular information that is not currently available in the operating room, helping to guide decisions during tumor removal, particularly at the tumor margins where the stakes are highest. In previous work published in PNAS in 2024, the team’s measurements were made in the hospital during surgery; in the new study, mass spectrometry data were recorded remotely and compared against the available clinical information, demonstrating that a very simple and quick measurement can carry high discriminating power between diseased and non-diseased tissue while also providing information on tumor grade and mutation status.

The research team included Shahi and Cooks along with Quiñones-Hinojosa; Michaelides; Diogo Moniz Garcia, a former Mayo Clinic postdoctoral fellow now a neurosurgery resident at Washington University in St. Louis; and Aleeshba N. Basil of the Mayo Clinic. Kenneth Lane Virgin of Indiana University School of Medicine, previously affiliated with Purdue’s Aston Laboratories for Mass Spectrometry, also contributed. Shahi and Cooks are members of the Purdue Institute for Cancer Research and work in the Analytical Chemistry group in Purdue’s College of Science. The work was supported by the National Institutes of Health, including the National Cancer Institute’s Innovative Molecular Analysis Technologies Program and the National Center for Advancing Translational Sciences, along with corporate support from Waters Corporation. Specimens came from the Mayo Clinic Florida Neurosurgery BRIDGE Biobank, a central nervous system bioresource built on patient-derived samples.

With the 86-sample study complete, the team’s next step is a similar study involving more than 50 patients in which the technique is used during surgery itself, which Cooks says would pave the way for a clinical trial to be proposed. If those trials succeed, the three-minute molecular readout could become a routine companion to the surgeon’s eye and the pathologist’s microscope, turning one of neurosurgery’s most persistent blind spots into measurable, actionable data at the precise moment it matters most.

Subject of Research: Rapid intraoperative mass spectrometry metabolite ratiomics for glioma margin diagnosis and classification during brain surgery

Article Title: Mass spectrometry offers faster look at the edges of brain tumors

Article References: Mass spectrometry offers faster look at the edges of brain tumors. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: glioma, mass spectrometry, brain tumor margins, ambient ionization, syringe touch spray, tumor resection, metabolite ratiomics, intraoperative diagnostics, Purdue University, Mayo Clinic, PNAS, targeted therapy